Arca
Skip to content
Tools
Tools

CRHR1: Corticotropin-releasing factor receptor 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

G protein-coupled receptor for CRH and UCN stress hormones, which plays a central role in whole body adaptation to stress.

  • Drugs that act on it: 5
  • Approved: 1
  • In phases 1 to 3: 4
  • Sponsors: 3

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CRHR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule

Approved1

  • Crinecerfont

Phase 31

  • Pexacerfont

Phase 23

  • Emicerfont
  • ONO-2333MS
  • Verucerfont

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    Modalities

    Drugs on this target by ChEMBL molecule type.

    • Small molecule5100%

    The Landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Corticotropin releasing factor receptor 1 antagonist.
    CrinecerfontApprovedNeurocrine BiosciencesSmall moleculeAntagonist—4—
    PexacerfontPhase 3Bristol-Myers SquibbSmall moleculeAntagonist—0—
    EmicerfontPhase 2GSKSmall moleculeAntagonist—0—
    ONO-2333MSPhase 2—Small moleculeAntagonist—0—
    VerucerfontPhase 2GSKSmall moleculeAntagonist—0—

    Open Trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 4 in all, from ClinicalTrials.gov.

    Diseases Most Associated With It

    Open Targets association score, 0 to 1; all associations
    Intelligence
    0.32
    Neurodegenerative disease
    0.31
    DNA methylation
    0.28
    Cancer
    0.27
    Peptic ulcer disease
    0.27
    Gastroesophageal reflux disease
    0.27
    Prostate carcinoma
    0.23
    Inherited hemoglobinopathy
    0.22

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1800, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P34998, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.